Skip to main content
Erschienen in: Supportive Care in Cancer 7/2015

01.07.2015 | Original Article

Assessing the response to opioids in cancer patients: a methodological proposal and the results

verfasst von: O. Corli, A. Roberto, M. T. Greco, M. Montanari

Erschienen in: Supportive Care in Cancer | Ausgabe 7/2015

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The efficacy of treatment with opioids in cancer pain is variable. To evaluate this variability, we (1) applied two parameters, changes in pain intensity (PI) and opioid daily doses (DDs), to distinguish different responses to opioids. The need to switch to another opioid was recorded. We then (2) evaluated the distribution of the responses depending on these parameters, alone and taken together, in cancer patients with pain.

Methods

The cutoffs between positive and negative responses related to PI and DD were defined on the basis of the literature. For PI, responders were patients who obtained simultaneously a decrease of 30 % or more and a final score ≤4 points (numerical rating scale 0 to 10). For DD changes, we applied the opioid escalation index percentage, a positive response corresponding to a dose increase ≤5 %. These criteria were applied to 201 cancer patients treated with WHO step III “strong” opioids for 21 days. The results were mainly analyzed case by case.

Results

Of the patients, 63.7 % obtained a positive analgesic response and 80.1 % a dose-related positive response. Combining the parameters, the response was double positive in 55.2 % of cases, double negative in 11.4 %, a good analgesic response with a large dose escalation in 8.5 %, and no pain relief with a stable dose in 24.9 %. Switches were made 21 times, 15 because of the lack of analgesia.

Conclusions

Different degrees of response to opioids were observed, PI and DD changes both contributing. Only over half the patients had a full positive response.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Ahmedzai S, Brooks D (1997) Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy, and quality of life. The TTS-Fentanyl Comparative Trial Group. J Pain Symptom Manag 13:254–261CrossRef Ahmedzai S, Brooks D (1997) Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy, and quality of life. The TTS-Fentanyl Comparative Trial Group. J Pain Symptom Manag 13:254–261CrossRef
2.
Zurück zum Zitat Apolone G, Corli O, Caraceni A, Negri E, Deandrea S, Montanari M, Greco MT (2009) Pattern and quality of care of cancer pain management. Results from the Cancer Pain Outcome Research Study Group. Br J Cancer 100:1566–1574CrossRefPubMedCentralPubMed Apolone G, Corli O, Caraceni A, Negri E, Deandrea S, Montanari M, Greco MT (2009) Pattern and quality of care of cancer pain management. Results from the Cancer Pain Outcome Research Study Group. Br J Cancer 100:1566–1574CrossRefPubMedCentralPubMed
3.
Zurück zum Zitat Bruera E, Belzile M, Pituskin E, Fainsinger R, Darke A, Harsanyi Z, Babul N, Ford I (1998) Randomized, double-blind, cross-over trial comparing safety and efficacy of oral controlled-release oxycodone with controlled-release morphine in patients with cancer pain. J Clin Oncol 16:3222–3229PubMed Bruera E, Belzile M, Pituskin E, Fainsinger R, Darke A, Harsanyi Z, Babul N, Ford I (1998) Randomized, double-blind, cross-over trial comparing safety and efficacy of oral controlled-release oxycodone with controlled-release morphine in patients with cancer pain. J Clin Oncol 16:3222–3229PubMed
4.
Zurück zum Zitat Bruera E, Palmer JL, Bosnjak S, Rico MA, Moyano J, Sweeney C, Strasser F, Willey J, Bertolino M, Mathias C, Spruyt O, Fisch MJ (2004) Methadone versus morphine as a first-line strong opioid for cancer pain: a randomized, double-blind study. J Clin Oncol 22:185–192CrossRefPubMed Bruera E, Palmer JL, Bosnjak S, Rico MA, Moyano J, Sweeney C, Strasser F, Willey J, Bertolino M, Mathias C, Spruyt O, Fisch MJ (2004) Methadone versus morphine as a first-line strong opioid for cancer pain: a randomized, double-blind study. J Clin Oncol 22:185–192CrossRefPubMed
5.
Zurück zum Zitat Caraceni A, Hanks G, Kaasa S, Bennett MI, Brunelli C, Cherny N, Dale O, De Conno F, Fallon M, Hanna M, Haugen DF, Juhl G, King S, Klepstad P, Laugsand EA, Maltoni M, Mercadante S, Nabal M, Pigni A, Radbruch L, Reid C, Sjogren P, Stone PC, Tassinari D, Zeppetella G (2012) Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol 13:e58–e68CrossRefPubMed Caraceni A, Hanks G, Kaasa S, Bennett MI, Brunelli C, Cherny N, Dale O, De Conno F, Fallon M, Hanna M, Haugen DF, Juhl G, King S, Klepstad P, Laugsand EA, Maltoni M, Mercadante S, Nabal M, Pigni A, Radbruch L, Reid C, Sjogren P, Stone PC, Tassinari D, Zeppetella G (2012) Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol 13:e58–e68CrossRefPubMed
6.
Zurück zum Zitat Caraceni A, Pigni A, Brunelli C (2011) Is oral morphine still the first choice opioid for moderate to severe cancer pain? A systematic review within the European Palliative Care Research Collaborative guidelines project. Palliat Med 25:402–409CrossRefPubMed Caraceni A, Pigni A, Brunelli C (2011) Is oral morphine still the first choice opioid for moderate to severe cancer pain? A systematic review within the European Palliative Care Research Collaborative guidelines project. Palliat Med 25:402–409CrossRefPubMed
7.
Zurück zum Zitat Cheng KFTD, Ling WM, Chan CWH (2005) Measuring symptom prevalence, severity and distress of cancer survivors. Clin Eff Nurs 9:154–160CrossRef Cheng KFTD, Ling WM, Chan CWH (2005) Measuring symptom prevalence, severity and distress of cancer survivors. Clin Eff Nurs 9:154–160CrossRef
8.
Zurück zum Zitat Clark AJ, Ahmedzai SH, Allan LG, Camacho F, Horbay GL, Richarz U, Simpson K (2004) Efficacy and safety of transdermal fentanyl and sustained-release oral morphine in patients with cancer and chronic non-cancer pain. Curr Med Res Opin 20:1419–1428CrossRefPubMed Clark AJ, Ahmedzai SH, Allan LG, Camacho F, Horbay GL, Richarz U, Simpson K (2004) Efficacy and safety of transdermal fentanyl and sustained-release oral morphine in patients with cancer and chronic non-cancer pain. Curr Med Res Opin 20:1419–1428CrossRefPubMed
10.
Zurück zum Zitat Corli O, Montanari M, Deandrea S, Greco MT, Villani W, Apolone G (2012) An exploratory analysis on the effectiveness of four strong opioids in patients with cancer pain. Pain Med 13:897–907CrossRefPubMed Corli O, Montanari M, Deandrea S, Greco MT, Villani W, Apolone G (2012) An exploratory analysis on the effectiveness of four strong opioids in patients with cancer pain. Pain Med 13:897–907CrossRefPubMed
11.
Zurück zum Zitat Corli O, Montanari M, Greco MT, Brunelli C, Kaasa S, Caraceni A, Apolone G (2012) How to evaluate the effect of pain treatments in cancer patients: Results from a longitudinal outcomes and endpoint Italian cohort study Eur J Pain 17: 858–866 Corli O, Montanari M, Greco MT, Brunelli C, Kaasa S, Caraceni A, Apolone G (2012) How to evaluate the effect of pain treatments in cancer patients: Results from a longitudinal outcomes and endpoint Italian cohort study Eur J Pain 17: 858–866
12.
Zurück zum Zitat Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT, Haythornthwaite JA, Jensen MP, Kerns RD, Ader DN, Brandenburg N, Burke LB, Cella D, Chandler J, Cowan P, Dimitrova R, Dionne R, Hertz S, Jadad AR, Katz NP, Kehlet H, Kramer LD, Manning DC, McCormick C, McDermott MP, McQuay HJ, Patel S, Porter L, Quessy S, Rappaport BA, Rauschkolb C, Revicki DA, Rothman M, Schmader KE, Stacey BR, Stauffer JW, von Stein T, White RE, Witter J, Zavisic S (2008) Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain 9:105–121CrossRefPubMed Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT, Haythornthwaite JA, Jensen MP, Kerns RD, Ader DN, Brandenburg N, Burke LB, Cella D, Chandler J, Cowan P, Dimitrova R, Dionne R, Hertz S, Jadad AR, Katz NP, Kehlet H, Kramer LD, Manning DC, McCormick C, McDermott MP, McQuay HJ, Patel S, Porter L, Quessy S, Rappaport BA, Rauschkolb C, Revicki DA, Rothman M, Schmader KE, Stacey BR, Stauffer JW, von Stein T, White RE, Witter J, Zavisic S (2008) Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain 9:105–121CrossRefPubMed
13.
Zurück zum Zitat Farrar JT, Portenoy RK, Berlin JA, Kinman JL, Strom BL (2000) Defining the clinically important difference in pain outcome measures. Pain 88:287–294CrossRefPubMed Farrar JT, Portenoy RK, Berlin JA, Kinman JL, Strom BL (2000) Defining the clinically important difference in pain outcome measures. Pain 88:287–294CrossRefPubMed
14.
Zurück zum Zitat Farrar JT, Pritchett YL, Robinson M, Prakash A, Chappell A (2010) The clinical importance of changes in the 0 to 10 numeric rating scale for worst, least, and average pain intensity: analyses of data from clinical trials of duloxetine in pain disorders. J Pain 11:109–118CrossRefPubMed Farrar JT, Pritchett YL, Robinson M, Prakash A, Chappell A (2010) The clinical importance of changes in the 0 to 10 numeric rating scale for worst, least, and average pain intensity: analyses of data from clinical trials of duloxetine in pain disorders. J Pain 11:109–118CrossRefPubMed
15.
Zurück zum Zitat Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole RM (2001) Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 94:149–158CrossRefPubMed Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole RM (2001) Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 94:149–158CrossRefPubMed
16.
Zurück zum Zitat Heiskanen TE, Ruismaki PM, Seppala TA, Kalso EA (2000) Morphine or oxycodone in cancer pain? Acta Oncol 39:941–947CrossRefPubMed Heiskanen TE, Ruismaki PM, Seppala TA, Kalso EA (2000) Morphine or oxycodone in cancer pain? Acta Oncol 39:941–947CrossRefPubMed
17.
Zurück zum Zitat Kaasa SAG, Klepstad P, Loge JH, Hjermstad MJ, Corli O, Strasser F, Heiskanen T, Costantini M, Zagonel V, Gronvold M, Fainsinger R, Jensen MP, Farrar JT, McQuay H, Rothrock NE, Cleary J, Sepulveda C, Deguines C, Caraceni A (2011) Expert conference on cancer pain assessment and classification—the need for international consensus: working proposal on international standards. BMJ Support Palliat Care 1:281–287CrossRefPubMed Kaasa SAG, Klepstad P, Loge JH, Hjermstad MJ, Corli O, Strasser F, Heiskanen T, Costantini M, Zagonel V, Gronvold M, Fainsinger R, Jensen MP, Farrar JT, McQuay H, Rothrock NE, Cleary J, Sepulveda C, Deguines C, Caraceni A (2011) Expert conference on cancer pain assessment and classification—the need for international consensus: working proposal on international standards. BMJ Support Palliat Care 1:281–287CrossRefPubMed
18.
Zurück zum Zitat Knotkova H, Fine PG, Portenoy RK (2009) Opioid rotation: the science and the limitations of the equianalgesic dose table. J Pain Symptom Manag 38:426–439CrossRef Knotkova H, Fine PG, Portenoy RK (2009) Opioid rotation: the science and the limitations of the equianalgesic dose table. J Pain Symptom Manag 38:426–439CrossRef
19.
Zurück zum Zitat Koyyalagunta D, Bruera E, Solanki DR, Nouri KH, Burton AW, Toro MP, Bruel BM, Manchikanti L (2012) A systematic review of randomized trials on the effectiveness of opioids for cancer pain. Pain Physician 15:ES39–ES58PubMed Koyyalagunta D, Bruera E, Solanki DR, Nouri KH, Burton AW, Toro MP, Bruel BM, Manchikanti L (2012) A systematic review of randomized trials on the effectiveness of opioids for cancer pain. Pain Physician 15:ES39–ES58PubMed
20.
Zurück zum Zitat Lauretti GR, Oliveira GM, Pereira NL (2003) Comparison of sustained-release morphine with sustained-release oxycodone in advanced cancer patients. Br J Cancer 89:2027–2030CrossRefPubMedCentralPubMed Lauretti GR, Oliveira GM, Pereira NL (2003) Comparison of sustained-release morphine with sustained-release oxycodone in advanced cancer patients. Br J Cancer 89:2027–2030CrossRefPubMedCentralPubMed
21.
Zurück zum Zitat Lowe SS, Nekolaichuk CL, Fainsinger RL, Lawlor PG (2008) Should the rate of opioid dose escalation be included as a feature in a cancer pain classification system? J Pain Symptom Manag 35:51–57CrossRef Lowe SS, Nekolaichuk CL, Fainsinger RL, Lawlor PG (2008) Should the rate of opioid dose escalation be included as a feature in a cancer pain classification system? J Pain Symptom Manag 35:51–57CrossRef
22.
Zurück zum Zitat Mercadante S, Caraceni A (2011) Conversion ratios for opioid switching in the treatment of cancer pain: a systematic review. Palliat Med 25:504–515CrossRefPubMed Mercadante S, Caraceni A (2011) Conversion ratios for opioid switching in the treatment of cancer pain: a systematic review. Palliat Med 25:504–515CrossRefPubMed
23.
Zurück zum Zitat Mercadante S, Fulfaro F, Casuccio A, Barresi L (1999) Investigation of an opioid response categorization in advanced cancer patients. J Pain Symptom Manag 18:347–352CrossRef Mercadante S, Fulfaro F, Casuccio A, Barresi L (1999) Investigation of an opioid response categorization in advanced cancer patients. J Pain Symptom Manag 18:347–352CrossRef
24.
Zurück zum Zitat Mercadante S, Porzio G, Ferrera P, Fulfaro F, Aielli F, Verna L, Villari P, Ficorella C, Gebbia V, Riina S, Casuccio A, Mangione S (2008) Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management. Eur J Pain 12:1040–1046CrossRefPubMed Mercadante S, Porzio G, Ferrera P, Fulfaro F, Aielli F, Verna L, Villari P, Ficorella C, Gebbia V, Riina S, Casuccio A, Mangione S (2008) Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management. Eur J Pain 12:1040–1046CrossRefPubMed
25.
Zurück zum Zitat Mucci-LoRusso P, Berman BS, Silberstein PT, Citron ML, Bressler L, Weinstein SM, Kaiko RF, Buckley BJ, Reder RF (1998) Controlled-release oxycodone compared with controlled-release morphine in the treatment of cancer pain: a randomized, double-blind, parallel-group study. Eur J Pain 2:239–249CrossRefPubMed Mucci-LoRusso P, Berman BS, Silberstein PT, Citron ML, Bressler L, Weinstein SM, Kaiko RF, Buckley BJ, Reder RF (1998) Controlled-release oxycodone compared with controlled-release morphine in the treatment of cancer pain: a randomized, double-blind, parallel-group study. Eur J Pain 2:239–249CrossRefPubMed
26.
Zurück zum Zitat Payne R, Mathias SD, Pasta DJ, Wanke LA, Williams R, Mahmoud R (1998) Quality of life and cancer pain: satisfaction and side effects with transdermal fentanyl versus oral morphine. J Clin Oncol 16:1588–1593PubMed Payne R, Mathias SD, Pasta DJ, Wanke LA, Williams R, Mahmoud R (1998) Quality of life and cancer pain: satisfaction and side effects with transdermal fentanyl versus oral morphine. J Clin Oncol 16:1588–1593PubMed
27.
Zurück zum Zitat Serlin RC, Mendoza TR, Nakamura Y, Edwards KR, Cleeland CS (1995) When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain 61:277–284CrossRefPubMed Serlin RC, Mendoza TR, Nakamura Y, Edwards KR, Cleeland CS (1995) When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain 61:277–284CrossRefPubMed
28.
Zurück zum Zitat Spichiger E, Muller-Frohlich C, Denhaerynck K, Stoll H, Hantikainen V, Dodd M (2011) Symptom prevalence and changes of symptoms over ten days in hospitalized patients with advanced cancer: a descriptive study. Eur J Oncol Nurs 15:95–102CrossRefPubMed Spichiger E, Muller-Frohlich C, Denhaerynck K, Stoll H, Hantikainen V, Dodd M (2011) Symptom prevalence and changes of symptoms over ten days in hospitalized patients with advanced cancer: a descriptive study. Eur J Oncol Nurs 15:95–102CrossRefPubMed
29.
Zurück zum Zitat Tranmer JE, Heyland D, Dudgeon D, Groll D, Squires-Graham M, Coulson K (2003) Measuring the symptom experience of seriously ill cancer and noncancer hospitalized patients near the end of life with the memorial symptom assessment scale. J Pain Symptom Manag 25:420–429CrossRef Tranmer JE, Heyland D, Dudgeon D, Groll D, Squires-Graham M, Coulson K (2003) Measuring the symptom experience of seriously ill cancer and noncancer hospitalized patients near the end of life with the memorial symptom assessment scale. J Pain Symptom Manag 25:420–429CrossRef
30.
Zurück zum Zitat van Seventer R, Smit JM, Schipper RM, Wicks MA, Zuurmond WW (2003) Comparison of TTS-fentanyl with sustained-release oral morphine in the treatment of patients not using opioids for mild-to-moderate pain. Curr Med Res Opin 19:457–469CrossRefPubMed van Seventer R, Smit JM, Schipper RM, Wicks MA, Zuurmond WW (2003) Comparison of TTS-fentanyl with sustained-release oral morphine in the treatment of patients not using opioids for mild-to-moderate pain. Curr Med Res Opin 19:457–469CrossRefPubMed
Metadaten
Titel
Assessing the response to opioids in cancer patients: a methodological proposal and the results
verfasst von
O. Corli
A. Roberto
M. T. Greco
M. Montanari
Publikationsdatum
01.07.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Supportive Care in Cancer / Ausgabe 7/2015
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-014-2536-1

Weitere Artikel der Ausgabe 7/2015

Supportive Care in Cancer 7/2015 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.